# A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

Study · id `cardio:ct-nct07816198` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07816198](<https://clinicaltrials.gov/study/NCT07816198>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07816198

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 354 participants.

## Technical summary

Registry record NCT07816198. Randomized; double masking; primary purpose treatment. Start 2026-09-30 (anticipated); primary completion 2028-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 354 participants (planned count; ClinicalTrials.gov record NCT07816198, source copy `cardio:ctgov-nct07816198-2026-09-16`, retrieved 2026-10-26)
- Planned start: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT07816198, source copy `cardio:ctgov-nct07816198-2026-09-16`, retrieved 2026-10-26)
- Primary completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07816198, source copy `cardio:ctgov-nct07816198-2026-09-16`, retrieved 2026-10-26)
- Completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07816198, source copy `cardio:ctgov-nct07816198-2026-09-16`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07816198-2026-09-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): AD-233A
- Intervention (Drug): AD-233B
- Intervention (Drug): AD-233C
- Intervention (Drug): AD-233D
- Intervention (Drug): AD-233A Placebo
- Intervention (Drug): AD-233B Placebo
- Lead sponsor: Addpharma Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Addpharma Inc. (`cardio:org-addpharma-inc`)

## Provenance

Content hash: 25ba40165541f0009a554ca4c9b35fe0ce42a9626bbc54b4fd95a613545ccde2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
